Device Trial Radar · NCT04506086
Feasibility Study to Evaluate Outpatient Blinatumomab in Subjects With Minimal Residual Disease (MRD) of B-precursor Acute Lymphoblastic Leukemia (ALL)
Last checked: Nov 19, 2026Latest source record: May 18, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
10
Actual
Start
Aug 26, 2021
Primary completion
Jul 4, 2024
Study completion Sep 16, 2024
Sponsor
- Lead sponsor
- AmgenNot on our public-company list
- Sponsor type
- Industry
- First posted
- Aug 10, 2020
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 18 years, up to 99 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The study aims to determine the safety and feasibility of complete outpatient blinatumomab administration for subjects with minimal/measurable residual disease (MRD) of B-precursor Acute Lymphoblastic Leukemia (ALL).
Conditions
- B-precursor Acute Lymphoblastic Leukemia
Interventions
BlinatumomabDrug
Participants will receive blinatumomab continuous IV infusion for a maximum of 4 cycles. Each cycle is 6 weeks in duration consisting of 4 weeks of treatment and 2 weeks of rest.
Current Wearable Heatlth Monitoring System (CWHMS)Device
The study will use the CWHMS device to monitor participants' vital signs while they are at home.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Grade 3 and/or 4 Cytokine Release Syndrome (CRS), Neurotoxicity (NT) or Any Adverse Events Resulting in Hospitalization During MDMPTime frame: Cycle 1: Day 1 to Day 3; Cycle 2: Day 1 and Day 2
Locations
12 sites in 1 country. Site status is shown where the registry gives one.
City of Hope National Medical Center
Duarte, California
University of California Los Angeles
Los Angeles, California
University of California Irvine
Orange, California
9 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.